Chris Chapman

Vice President and General Manager

U.S. Prescription Business


Chris Chapman is Vice President and General Manager for the U.S. Prescription Business of Galderma.  As the leader of the company’s largest prescription business globally, Chris manages Galderma’s broad portfolio of prescription medications including the full line of products that treat acne, psoriasis, eczema and rosacea.  He also oversees Galderma® CareConnect, a patient savings card program that offers discounts to patients on the quality dermatology prescription medications offered by Galderma. 

Chris joined Galderma in 2015, and in his previous position as Vice President of Strategic Access was responsible for commercial payer account management and contracting, trade account management and branded consumer rebate programs.  During his tenure, Chris developed and launched the Galderma® CareConnect program. The program has grown to more than 46,000 pharmacies and served more than 790,000 unique patients, and has filled more than 1,400,000 prescriptions.  In 2017 Galderma® CareConnect program was a Silver Winner in the PMC360 Magazine Trailblazer Awards in the Persistence/Adherence Program category.  

Prior to joining Galderma, Chris spent 20 years at Pfizer in roles of increasing responsibility, including leading the U.S. Pharmaceutical Contracting and Pricing Organization, the South Regional Payer Prescription Business, National Healthcare Operations National Account Management Team and numerous leadership roles throughout the organization.  

Chris also served as the Executive Director of Managed Markets and Contracting for Medicis Pharmaceutical Corporation, in addition to co-founding and serving as the Senior Principal of The Core Access Group, a biopharmaceutical consulting firm dedicated to the development of data driven market access strategies and enabling technologies.   

Chris holds a Bachelor of Science from Towson University in Maryland and is an active member of the Phi Alpha Theta International Honor Society for History.